Experimental combo shows promise for Tough-to-Treat cancers
NCT ID NCT04798781
First seen Nov 20, 2025 · Last updated May 24, 2026 · Updated 19 times
Summary
This study tested a combination of two drugs—telatinib and Keytruda—in 16 people with advanced stomach or liver cancer that had not responded to prior treatments. The goal was to see if the combo could slow cancer growth or improve survival. Participants received both drugs and were monitored for side effects and how long they lived without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CS Cancer Beverly Hills
Beverly Hills, California, 90211, United States
-
CS Cancer at The Angeles Clinic and Research Institute
Los Angeles, California, 90025, United States
-
CS Cancer at the Samuel Oschin Cancer Center
Los Angeles, California, 90048, United States
Conditions
Explore the condition pages connected to this study.